Exbio — Research products — Antibodies — Cytoskeleton and ECM — Anti-Tenascin Purified

Anti-Tenascin Purified

Anti-Tenascin Purified
Regulatory status
RUO
Antigen
Tenascin
Clone
T2H5
Format
Purified
Reactivity
Human
Application
IP, WB, IHC(P)
Variant
0.1 mg
11-370-C100
In stock
150.00 USD
0.025 mg
11-370-C025
Delivery 1 week
75.00 USD
Variant
0.1 mg
11-261-C100
In stock
150.00 USD
0.1 mg
11-261-C100
In stock
75.00 USD
Contact distributor
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The antibody T2H5 recognizes tenascin, a large hexameric extracellular matrix glycoprotein.
Application
IP, WB, IHC(P)
Application details
Immunohistochemistry (paraffin sections): Immunohistochemical detection of tenascin is valuable for studies of tissue differentiation and tumour growth. The antibody T2H5 is excellent for staining of paraffin-embedded tissue sections.
Western blotting: Recommended dilution: 1-2 μg/ml.
Reactivity
Human
Immunogen
Protein preparation from a homogenate of a human mammary tumour specimen.
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
TN, Hexabrachion, Cytotactin, Neuronectin
11-370_IHC
Immunohistochemistry staining of tonsil (paraffin-embedded sections) with anti-human Tenascin (T2H5).
11-370_FC_Histogram
Separation of U-87 MG cells stained using anti-Tenascin (T2H5) purified antibody (concentration in sample 12,0 μg/ml, GAM FITC, red-filled) from U-87 MG cells unstained by primary antibody (GAM FITC, black-dashed) in flow cytometry analysis (surface staining).
11-370_ICC
Immunocytochemistry staining of tenascin in U-87 MG cells using purified mouse monoclonal antibody T2H7 (concentration in sample 12 μg/ml, GAM FITC, right picture) vs. Hoechst 34580 nuclear staining (left picture).
11-370_WB
Western blotting analysis of human tenascin using mouse monoclonal antibody T2H5 on lysates of U87-MG cell line and Jurkat cell line (tenascin non-expressing cell line; negative control) under non-reducing and reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse anti-tenascin monoclonal antibody followed by IRDye800-conjugated anti-mouse secondary antibody. Tenascin was detected slightly above 250 kDa.

Product specific references:

Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002 Dec;38(18):2362-70.
PubMed
Gulubova M: Immunohistochemical localization of collagen type III and type IV, laminin, tenascin and alpha-smooth muscle actin (alphaSMA) in the human liver in peliosis. Pathol Res Pract. 2002;198(12):803-12.
PubMed
Faustino AM, van Garderen E, Schalken JA, Nederbragt H: Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. J Comp Pathol. 2002 Jan;126(1):1-8.
PubMed
Tokes AM, Hortovanyi E, Csordas G, Kulka J, Mozes G, Hatalyak A, Kadar A: Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res. 1999 Jan-Feb;19(1A):175-9.
PubMed
Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Scott Budinger GS, Raparia K, Tamaki Z, Varga J: Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016 Jun 3;7:11703
PubMed
Seyger MM, van Bruggen MC, Hardeman HK, van den Hoogen FH, Berden JH, van den Born J, de Jong EM: Decreased staining of heparan sulfate in non-lesional skin of a subgroup of patients with systemic lupus erythematosus. Acta Derm Venereol. 1998 Sep;78(5):326-30.
PubMed
Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997 Aug;137(2):171-8
PubMed
Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, de Jongh GJ, Schalkwijk J: Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127(6):571-4
PubMed
Mansour RG, Stamper L, Jaeger F, McGuire E, Fouda G, Amos J, Barbas K, Ohashi T, Alam SM, Erickson H, Permar SR: The presence and anti-HIV-1 function of tenascin C in breast milk and genital fluids. PLoS One. 2016 May 16;11(5):e0155261.
PubMed
Variant
0.1 mg
11-370-C100
In stock
150.00 USD
0.025 mg
11-370-C025
Delivery 1 week
75.00 USD
Variant
0.1 mg
11-261-C100
In stock
150.00 USD
0.1 mg
11-261-C100
In stock
75.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product